A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
Patients will be randomized to one of 3 study arms:
Arm 1 - Peptamen drinks + multivitamin and mineral supplement, taken in addition to regular diet for 4 months Arm 2 - NuBasics drinks or equivalent amounts of NuBasics soups or bars + multivitamin and mineral supplement, taken in addition to regular diet for 4 months Arm 3 - Multivitamin and mineral supplement, taken in addition to regular diet for 4 months.
At months 0, 2, and 4, patients will be assessed for weight, body cell mass, patient-reported physical activity level, and dietary intake (by 24-hour dietary recall). At months 2 and...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV infection.
- • Stable weight.
- • CD4+ cell count \<200 cells/mm3.
- • Life expectancy of at least 6 months.
- • Parent or legal guardian to sign written, informed consent for patients \< 18 years old.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with any of the following symptoms or conditions are excluded:
- • Active opportunistic infection, requiring acute treatment.
- • Malignancy (other than stable cutaneous Kaposi's sarcoma that does not require systemic chemotherapy).
- • Diabetes mellitus or other conditions requiring special dietary restrictions.
- • Body mass index (BMI) \>= 29.0 kg/m2.
- • Disorders or conditions that, in the treating clinician's opinion, may prevent adequate compliance with protocol requirements.
- Concurrent Medication:
- Excluded:
- • Growth hormone.
- • Megestrol acetate (Megace).
- • Cyproheptadine (Periactin).
- • Dronabinol (Marinol).
- • Thalidomide.
- • Anabolic steroids (e.g., nandrolone decanoate)(Deca-durabolin).
- • Pharmacologic-dose corticosteroids (e.g., \> 15 mg/day prednisone equivalent)
- NOTE:
- • Men requiring testosterone replacement therapy for documented hypogonadism may be enrolled.
- • Caloric nutritional supplements deemed by the clinician to promote weight gain or maintenance.
- Patients with the following prior condition are excluded:
- • History of phenylketonuria.
- Prior Medication:
- Excluded within the past 2 weeks:
- • Use of caloric nutritional supplements for more than 5 days deemed by the clinician to promote weight gain or maintenance.
- Excluded within the past 30 days:
- • Growth hormone.
- • Megestrol acetate (Megace).
- • Cyproheptadine (Periactin).
- • Dronabinol (Marinol).
- • Thalidomide.
- • Anabolic steroids (e.g., nandrolone decanoate)(Deca-durabolin)
- • Pharmacologic-dose corticosteroids (e.g., \> 15 mg/day prednisone equivalent).
- NOTE:
- • Men requiring testosterone replacement therapy for documented hypogonadism may be enrolled.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
San Francisco, California, United States
Denver, Colorado, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
New Orleans, Louisiana, United States
Detroit, Michigan, United States
Camden, New Jersey, United States
Newark, New Jersey, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Portland, Oregon, United States
Baltimore, Maryland, United States
Albuquerque, New Mexico, United States
Washington, District Of Columbia, United States
Albuquerque, New Mexico, United States
Detroit, Michigan, United States
Patients applied
Trial Officials
Gilbert CL
Study Chair
Wheeler D
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials